Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more
Ckd Bio (063160) - Total Assets
Latest total assets as of September 2025: ₩295.23 Billion KRW
Based on the latest financial reports, Ckd Bio (063160) holds total assets worth ₩295.23 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ckd Bio - Total Assets Trend (2008–2024)
This chart illustrates how Ckd Bio’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ckd Bio - Asset Composition Analysis
Current Asset Composition (December 2024)
Ckd Bio's total assets of ₩295.23 Billion consist of 40.5% current assets and 59.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.4% |
| Accounts Receivable | ₩31.24 Billion | 11.0% |
| Inventory | ₩80.54 Billion | 28.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩6.45 Billion | 2.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Ckd Bio's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ckd Bio's current assets represent 40.5% of total assets in 2024, a decrease from 60.8% in 2008.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2024, down from 9.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 28.3% of total assets.
Ckd Bio Competitors by Total Assets
Key competitors of Ckd Bio based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Ckd Bio - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Ckd Bio generates 0.60x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Ckd Bio generates $ 3.06 in net profit.
Ckd Bio - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.92 | 1.24 | 1.66 |
| Quick Ratio | 0.24 | 0.53 | 0.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-11.51 Billion | ₩ 23.32 Billion | ₩ 37.60 Billion |
Ckd Bio - Advanced Valuation Insights
This section examines the relationship between Ckd Bio's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -3.2% |
| Total Assets | ₩284.49 Billion |
| Market Capitalization | $44.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ckd Bio's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Ckd Bio's assets decreased by 3.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Ckd Bio (2008–2024)
The table below shows the annual total assets of Ckd Bio from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩284.49 Billion | -3.16% |
| 2023-12-31 | ₩293.79 Billion | -6.02% |
| 2022-12-31 | ₩312.59 Billion | +4.71% |
| 2021-12-31 | ₩298.54 Billion | +5.32% |
| 2020-12-31 | ₩283.46 Billion | +21.48% |
| 2019-12-31 | ₩233.35 Billion | +26.46% |
| 2018-12-31 | ₩184.52 Billion | +2.81% |
| 2017-12-31 | ₩179.48 Billion | -0.79% |
| 2016-12-31 | ₩180.91 Billion | +6.02% |
| 2015-12-31 | ₩170.64 Billion | +3.38% |
| 2014-12-31 | ₩165.07 Billion | -5.94% |
| 2013-12-31 | ₩175.50 Billion | -5.35% |
| 2012-12-31 | ₩185.42 Billion | -6.49% |
| 2011-12-31 | ₩198.29 Billion | +67.66% |
| 2010-12-31 | ₩118.27 Billion | +6.30% |
| 2009-12-31 | ₩111.26 Billion | +17.30% |
| 2008-12-31 | ₩94.85 Billion | -- |